Case Study of a γ-Butyrolactone Alkylation with 1,3-Dimethyl-2-imidazolidinone as a Promoter
1,3-Dimethyl 2-imidazolidinone (DMI) is of lower toxicological risk than 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), hexamethyl-phosphorus triamide (HMPT), and hexamethylphosphoramide (HMPA). Formation of dialkylation byproducts is a common problem in lactone alkylation. DMI, used in...
Gespeichert in:
Veröffentlicht in: | Organic process research & development 2001-11, Vol.5 (6), p.609-611 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | 1,3-Dimethyl 2-imidazolidinone (DMI) is of lower toxicological risk than 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), hexamethyl-phosphorus triamide (HMPT), and hexamethylphosphoramide (HMPA). Formation of dialkylation byproducts is a common problem in lactone alkylation. DMI, used in stoichiometric amount, increases the rate of alkylation of γ-butyrolactone 1 by >30-fold, therefore minimizing the dialkylation in multi-kilogram preparations. The isolated yield of the monoalkylated product 2 is >90%. The reaction protocol is also demonstrated to work on other lactone substrates and alkylating agents. |
---|---|
ISSN: | 1083-6160 1520-586X |
DOI: | 10.1021/op010224h |